1. Immunogenicity and safety of a 12-valent pneumococcal conjugate vaccine in infants aged 6–10 weeks: a randomized double-blind active-controlled trial
- Author
-
Tuangtip Theerawit, Hun Kim, Ji Hwa Ryu, Jamaree Teeratakulpisarn, Seulgi Lee, An Kyung-Jun, Jonghoon Shin, Thanyawee Puthanakit, Jinhwan Shin, and Hayoung Lee
- Subjects
safety ,medicine.medical_specialty ,030231 tropical medicine ,Immunology ,Booster dose ,immunogenicity ,medicine.disease_cause ,Pediatrics ,Immunoglobulin G ,Pneumococcal conjugate vaccine ,12-valent pneumococcal conjugate vaccine ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Streptococcus pneumoniae ,medicine ,030212 general & internal medicine ,Adverse effect ,biology ,business.industry ,Incidence (epidemiology) ,Immunogenicity ,lcsh:RJ1-570 ,lcsh:Pediatrics ,infant ,Pediatrics, Perinatology and Child Health ,biology.protein ,Original Article ,business ,medicine.drug - Abstract
Background: Pneumococcal diseases among children aged 0.35 μg/mL was lower for some serotypes in the GBP411 group than in the comparator group (6B: 20.83% vs. 39.22%, P=0.047 and 19A: 58.33% vs. 90.20%, P97% of the subjects in each group achieved IgG concentrations of ≥0.35 μg/mL for all 12 serotypes. Increased immunogenicity was observed for some serotypes that showed significant intergroup differences after administration of the primary doses but not after the booster dose. We also found no significant intergroup difference in the overall incidence of solicited local adverse events. Furthermore, the overall incidence of solicited systemic adverse events was significantly lower in the GBP411 group than in the comparator vaccine group (79.59% vs. 98.04%; P=0.003).Conclusion: The GBP411 vaccine with a dosing schedule of 2p+1 may be immunogenic and safe for healthy infants.
- Published
- 2020